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HumanHuman brain chemistry is incompletely understood and better methodologies are needed. Traumatic
brain injury (TBI) causes metabolic perturbations, one result of which includes increased brain lactate
levels. Attention has largely focussed on glycolysis, whereby glucose is converted to pyruvate and lactate,
and is proposed to act as an energy source by feeding into neurons’ tricarboxylic acid (TCA) cycle, gener-
ating ATP. Also reportedly upregulated by TBI is the pentose phosphate pathway (PPP) that does not gen-
erate ATP but produces various molecules that are putatively neuroprotective, antioxidant and
reparative, in addition to lactate among the end products.
We have developed a novel combination of 13C-labelled cerebral microdialysis both to deliver
13C-labelled substrates into brains of TBI patients and recover the 13C-labelled metabolites, with high-
resolution 13C NMR analysis of the microdialysates. This methodology has enabled us to achieve the ﬁrst
direct demonstration in humans that the brain can utilise lactate via the TCA cycle. We are currently
using this methodology to make the ﬁrst direct comparison of glycolysis and the PPP in human brain.
In this article, we consider the application of 13C-labelled cerebral microdialysis for studying brain
energy metabolism in patients. We set this methodology within the context of metabolic pathways in
the brain, and 13C research modalities addressing them.
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glycolysis, which takes places in the cytosol and produces pyruvate, which enters
mitochondria and is converted into acetyl CoA that enters the TCA cycle.
Alternatively, pyruvate can stay in the cytosol and is converted into lactate that
is exported out of the cell. The pentose phosphate pathway (PPP) takes place in the
cytosol and is an alternative energy pathway that can be up-regulated after injury;
it is an important source of NADPH used to produce the reduced form of glutathione
(GSH) for preventing oxidative stress.1. Introduction
1.1. Need for better understanding of energy metabolism in the injured
human brain
Energy metabolism in the human brain is incompletely under-
stood, even in the normal uninjured state. Moreover, following
traumatic brain injury (TBI), a complex (and variable) sequence
of pathological processes arises, in which cerebral energy pertur-
bations appear to play a major role. A well-recognised feature is
elevation of brain extracellular lactate and the lactate/pyruvate
(L/P) ratio, associated with unfavourable clinical outcome
(Timofeev et al., 2011). TBI-induced pathologies evolve over the
scale of hours and days, and, despite treatment, may lead to a
range of clinical outcomes from good recovery to varying degrees
of disability or even death (Kolias et al., 2013). Historically, atten-
tion has focussed on ischaemia, leading to a deﬁciency in supply
of oxygen, glucose and other blood-borne nutrients, falling short
of the metabolic demands of the injured brain. Much has been
learned in neuro-critical care management of patients, so that
ischaemia is minimised by adopting modern protocol-driven ther-
apy designed to maintain adequate cerebral perfusion whilst
keeping intracranial pressure below a critical threshold. Survival
rates, and quality of survival, have thus improved. Despite these
advances, there is a growing recognition that, in some circum-
stances, diffusion barriers (Menon et al., 2004) or increased met-
abolic demands, e.g. by spreading depression (Parkin et al., 2005),
may adversely affect the balance between substrate supply and
demand, thus resulting in tissue hypoxia or reduced glucose
availability. In other settings, despite seemingly adequate provi-
sion of metabolic fuels and oxygen, the injured brain is unable
to efﬁciently utilise these substrates to generate cellular energy.
This has sometimes been termed ‘mitochondrial dysfunction’
although the exact basis of this process is not understood. In-
creased reliance on glycolysis, which produces a low yield of
ATP per molecule of glucose, followed by conversion of pyruvate
to lactate, is often regarded as a consequence of mitochondrial
dysfunction. Also, alternative pathways that consume glucose
may become upregulated, such as the pentose phosphate path-
way (PPP) that does not generate ATP but is potentially repara-
tive. There is therefore a need to improve our understanding of
the fundamental processes of brain energy metabolism, reﬁne
our clinical interventions to minimise this energy failure and, ulti-
mately, generate speciﬁc strategies to optimise clinical outcome.
Until recently, understanding of energy metabolism has arisen
through laboratory investigations, and the concepts applied to hu-
mans. Advances in technology are now enabling direct, detailed
exploration of metabolism in man. Techniques available include
microdialysis, nuclear magnetic resonance (NMR) spectroscopy,
mass spectrometry, and in vivo magnetic resonance spectroscopy
(MRS).In this article, we consider the application of the novel tech-
nique of 13C-labelled cerebral microdialysis that we have devel-
oped for studying brain energy metabolism in patients (Gallagher
et al., 2009). We set this methodology within the context of meta-
bolic pathways in the brain, and 13C research modalities addressing
them.
1.2. Fundamental biochemistry of energy metabolism
Energy metabolism is the overall process through which living
systems acquire and utilise the energy they need to carry out var-
ious functions. Humans, like other chemoorganotrophs, obtain this
energy by oxidising organic compounds, notably carbohydrates,
lipids and proteins. This energy is coupled to endergonic reactions
resulting in the synthesis of high-energy phosphate compounds,
speciﬁcally adenosine triphosphate (ATP). The primary organic
compound utilised by humans is glucose. ATP is generated by a se-
quence of three well-recognised processes (Fig. 1), as follows:
(a) Glycolysis: This is the linear pathway (also termed Embden–
Meyerhof–Parnas pathway, or the Embden–Meyerhof
pathway) by which glucose is converted (via several inter-
mediates) to pyruvate, thereby generating 2 molecules of
ATP per molecule of glucose. Glycolysis does not involve
molecular oxygen. After glycolysis, under aerobic conditions,
pyruvate is converted to acetyl CoA and enters the tricarboxylic
Fig. 2. Glucose (Glc) from the vasculature is metabolised to lactate (Lac) in
astrocytes, exported into the extra-cellular ﬂuid, taken up by neurons and
processed (via pyruvate (Pyr) and acetate (Ac)) by the TCA cycle. This spins off
glutamate (Glt), which is released and then taken up by astrocytes, which convert it
to glutamine (Gln), which is released into the extra-cellular ﬂuid and taken up by
neurons, which re-convert it to glutamate (Gallagher et al., 2009). Figure originally
published in Brain (Gallagher et al., 2009).
Fig. 3. Some examples of 13C-labelling patterns in brain metabolism, based on
results with singly labelled substrates (Gallagher et al., 2009; Tyson et al., 2003).
Turquoise ﬁlls indicate 13C atoms. Yellow highlight indicates the metabolic pathway
by which 13C-labelled lactate is processed via the TCA cycle, emerging as
13C-labelled glutamate or 13C-labelled glutamine that can be recovered in brain
microdialysates. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
Fig. 4. Upper panel: (a) Example of 13C NMR spectrum of brain microdialysate from
a TBI patient, who received perfusion with 2-13C acetate (4 mM) by a microdialysis
catheter via a craniotomy (CTO); red stars indicate 13C signals for glutamine C4, C3
and C2 indicating metabolism via TCA cycle. (b) 13C NMR spectrum of the 2-13C
acetate substrate solution prior to perfusing. (c) 13C NMR spectrum of brain
microdialysate from an unlabelled patient whose microdialysis catheter was
perfused with plain perfusion ﬂuid without labelled substrate. Lower panel: (a)
and (b) Examples of 13C NMR spectra of brain microdialysates from a TBI patient,
who received perfusion with 3-13C lactate (4 mM) by microdialysis catheters via a
craniotomy (CTO); red stars indicate 13C signals for glutamine C4, C3 and C2
indicating metabolism via TCA cycle. (c) 13C NMR spectrum of the 3-13C lactate
substrate solution prior to perfusing. (d) 13C NMR spectrum of brain microdialysate
from an unlabelled patient (as in Upper panel (c)). Abbreviations: see Fig. 2 legend.
For further details, see (Gallagher et al., 2009). Figures originally published in Brain
(Gallagher et al., 2009).
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tions, and/or if the mitochondria are dysfunctional, pyruvate
is converted by the enzyme lactate dehydrogenase to lactate,
while converting nicotinamide adenine dinucleotide (NADH)
to NAD+. The L/P ratio can therefore be used as an indicator
of the comparative degree of ‘‘aerobic’’ vs. ‘‘anaerobic’’
metabolism. One of the intermediates in glycolysis, glu-
cose-6-phosphate, can also be metabolised via the PPP ini-
tially generating nicotinamide adenine dinucleotide
phosphate (NADPH) and ribulose-5-phosphate that undergo
further reactions (see below). Both glycolysis and the PPP
occur in the cytosol.
(b) Tricarboxylic acid (TCA) cycle: This cyclical pathway (also
termed citric acid cycle or Krebs cycle) comprises a series
of 8 reactions that oxidise the acetyl group of acetyl-coen-
zyme A (acetyl-CoA) producing 3 molecules of NADH, one
molecule of ﬂavin adenine dinucleotide (FADH2), and one
molecule of guanosine triphosphate (GTP). The TCA cycle
takes place in mitochondria.(c) Oxidative phosphorylation: This is a process occurring in
mitochondria through which NADH and FADH2 from the
TCA cycle are oxidised by oxygen in the electron transport
chain resulting in the synthesis of further molecules of
ATP. Also, the succinate to fumarate step of the TCA cycle
takes place directly on part of the electron transport chain
(Complex 2) thereby promoting ATP synthesis.
Overall, one molecule of glucose, in the presence of oxygen, pro-
cessed via this three-stage pathway (glycolysis, TCA cycle and oxi-
dative phosphorylation), yields a net production of 36 molecules of
ATP.
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While glucose is recognised as the primary substrate in most or-
gans, including muscle, recent evidence suggests that the situation
in the brain is considerably more complex, particularly in relation
to the main cell types. The traditional view is that both glia and
neurones metabolise glucose as the preferred substrate via glycol-
ysis to pyruvate, which is converted to acetyl CoA and enters the
TCA cycle resulting in the generation of ATP by oxidative phos-
phorylation. Recent evidence suggests, however, that the neurones
may utilise lactate (classically perceived as a waste product) as an
energy substrate. Fig. 2 outlines a scheme of metabolic trafﬁcking
between astrocytes and neurons. This theory, later termed the
astrocyte-neuron lactate shuttle (ANLS) hypothesis, was originally
proposed (Pellerin and Magistretti 1994) as a result of in vitro
studies and has been later supported by studies in animals e.g.
(Tyson et al., 2003). Moreover, our recent microdialysis studies
using 13C-labelling have demonstrated that the injured human
brain can metabolise lactate via the TCA cycle (Gallagher et al.,
2009) (Figs. 3 and 4).
Cerebral metabolism following injury appears to differ from
that of the normal brain, although the full extent and nature of
these changes are poorly understood, especially in man. The
best-known metabolic characteristic of injured brain is a high L/P
ratio (>25 is interpreted as ischaemia or mitochondrial dysfunc-
tion) (Bellander et al., 2004; Hillered et al., 2006; Hillered et al.,
2005; Persson and Hillered 1992; Persson et al., 1996). Our study
of 233 TBI patients demonstrated that microdialysate L/P ratio
>25 predicted unfavourable outcome in a multivariate analysis in
addition to previously known predictors of outcome (Timofeev
et al., 2011).
Low extracellular lactate levels, associated with better out-
comes (Timofeev et al., 2011), might be because astrocytic glycol-
ysis-derived lactate is being efﬁciently taken up by neurons and
utilised via the TCA cycle (Gallagher et al., 2009). Conversely, high
extracellular lactate may result if neurons are too damaged to efﬁ-
ciently utilise the lactate being produced by astrocytes, i.e. uncou-
pling of neuronal and glial metabolism.Fig. 5. Simpliﬁed schematic of steps in glycolysis and the pentose phosphate pathway (PP
indicate 13C atoms. Abbreviations: Glc-6-P, glucose-6-phosphate; 6PGL, 6-phosphoglu
pyruvate.1.4. Alternative pathways
1.4.1. Pentose phosphate pathway
As well as the fundamental pathways outlined in Section 1.2,
other pathways may also be relevant, for example the PPP (Fig. 5),
also termed the hexose monophosphate shunt, a complex detour
(hence the name ‘‘shunt’’) that bypasses some of the steps of glycol-
ysis. Glucose enters the cell, and becomes phosphorylated to give
glucose-6-phosphate as in glycolysis, but then in the PPP it is
diverted through a different set of enzymatic reactions. Glucose-
6-phosphate is oxidised to 6-phosphogluconolactone by glucose-
6-phosphate dehydrogenase, the rate-limiting step of the PPP.
NADP+ is a cofactor, and NADPH is produced. Subsequently 6-phos-
phogluconolactone is converted to 6-phosphogluconate, and then
C1 of the 6-carbon sugar skeleton is lost as CO2, together with con-
version of NADP+ to NADPH, and formation of ribulose-5-phosphate
(5-carbon sugar, a pentose). The aforementioned steps are termed
the oxidative phase of the PPP. The subsequent steps are termed
the non-oxidative phase of the PPP, in which the 5-carbon skeleton
undergoes various transformations and recombinations generating
intermediatemolecules with 3–7 carbon atoms. The 5-carbon (pen-
tose) sugar ribose-5-phosphate can be utilised in nucleic acid syn-
thesis, providing reparative building blocks for the injured tissue,
while the 4-carbon sugar erythrose-4-phosphate can be utilised in
the synthesis of aromatic amino acids. The NADPH generated by
the oxidative phase of the PPP provides reducing equivalents for
the synthesis of fatty acids (e.g. for repairing injured tissue) and
for the formation of the reduced form of glutathione (GSH), an
essential co-factor for glutathione peroxidases (GPx), a family of en-
zymes that remove hydroperoxides, thereby combating oxidative
stress. While the activity of the PPP thus appears potentially repar-
ative, it neither consumes nor generates ATP. The exit-points of the
PPP involve the re-entry of products fructose-6-phosphate and
glyceraldehyde-3-phosphate (these can alternatively be recycled
back into the PPP to generate more NADPH) into the main stream
of glycolysis, producing pyruvate, which can enter mitochondria,
form acetate and enter the TCA cycle, or pyruvate can be converted
to lactate in the cytosol and exit into the extracellular ﬂuid.P), showing 13C labelling patterns resulting from 1,2-13C2 glucose substrate. Red ﬁlls
conolactone; F6P, fructose-6-phosphate; G3P, glyceraldehyde-3-phosphate; PYR,
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that enter the PPP lose 3 molecules of CO2 while converting 6 mol-
ecules of NADP+ to 6 molecules of NADPH, and producing 3 mole-
cules of ribulose-5-phosphate (5-carbon sugar) which, via several
intermediates (3–7 carbons), result in 2 molecules of fructose-6-
phosphate (6-carbon sugar) and 1 molecule of glyceraldehyde-3-
phosphate (3-carbon molecule). However the stoichiometry is
not necessarily so straightforward, as some of the 5-carbon and
4-carbon sugar intermediates can be taken out of the PPP by con-
version to nucleic acids and amino acids respectively, and some of
the fructose-6-phosphate (6-carbon sugar) and glyceraldehyde-3-
phosphate (3-carbon molecule) that are PPP products can be recy-
cled back into the PPP, potentially generating more NADPH, as
mentioned above.
Pre-clinical evidence from 13C-labelling and NMR suggests that
the utilisation of glucose following injury differs from normal, with
an increased ﬂux through the PPP, which is upregulated by cellular
stress, demonstrated in animals, e.g. brain injury (controlled corti-
cal impact or ﬂuid percussion injury) with brain tissue extracts
analysed ex vivo using 13C NMR (Bartnik et al., 2007; Bartnik
et al., 2005), or hypothermia with brain tissue extracts analysed
ex vivo by 1H-observe [13C-edited] spin-echo difference NMR
(Kaibara et al., 1999). The idea of an increased PPP ﬂux was sup-
ported by the results of an indirect measure in a small study of
TBI patients (n = 6) vs. healthy controls (n = 6), using arterio-jugu-
lar venous difference (AJVD) with 1,2-13C2 glucose (intravenous
infusion) as the substrate with gas chromatography–mass spec-
trometry (GC–MS) used for analysing the products including
13C-labelled lactate in arterial and jugular venous blood (Dusick
et al., 2007). However, the AJVD methodology could only produce
relevant 13C results in periods when the brain was showing net ex-
port of lactate, as opposed to net import, which can happen in
some periods (Dusick et al., 2007; Jalloh et al., 2013), and the ﬁnd-
ings of Dusick et al. have yet to be conﬁrmed in human brain di-
rectly. We are currently using 1,2-13C2 glucose substrate perfused
via cerebral microdialysis catheters in TBI patients, with analysis
of lactate 13C labelling in microdialysates, using 13C NMR (see
Section 3.1).
Using 1,2-13C2 glucose as the substrate, the products down-
stream of the PPP include lactate singly labelled at the C3 position,
showing as a singlet in the 13C NMR spectrum (Fig 5). Lactate pro-
duced via glycolysis (without going through the PPP) is doubly la-
belled with 13C at both the C3 and C2 positions of lactate within the
same molecule, showing as a doublet for C3 (Fig. 5), and a doublet
for C2. The ratio of C3 singlet to C3 doublet signal intensities (peak
area ratios) can be used as a measure of lactate production by PPP
vs. glycolysis. Bartnik and colleagues used this approach in pre-
clinical studies of brain injury in rats (Bartnik et al., 2007; Bartnik
et al., 2005). Brain tissue extracts from the control rats (uninjured,
sham-operated) in these studies showed lactate C3 doublet indic-
ative of glycolysis, while C3 singlet was undetectable, i.e. no
detectable lactate via the PPP (Bartnik et al., 2007; Bartnik et al.,
2005). In the same studies, for brain tissue extracts from the
brain-injured rats (controlled cortical impact or ﬂuid percussion
injury), Bartnik and colleagues reported detectable lactate C3 sin-
glet and C3 doublet, with up to 13% PPP which they calculated
using the lactate C3 singlet/doublet ratio (Bartnik et al., 2007; Bart-
nik et al., 2005). Endogenous lactate, which naturally contains 1.1%
13C at each position, also gives a singlet for each carbon. Therefore,
unless the endogenous lactate signal is negligible, the lactate sin-
glet C3 signal needs correcting to subtract any background contri-
bution from natural abundance, before calculating its ratio to the
C3 doublet. Endogenous extracellular lactate concentrations are
usually quite high (e.g. 2–4 mM) in brain microdialysates of TBI pa-
tients (Timofeev et al., 2011), and are readily detectable, even in
TBI patients without 13C labelling, by 13C NMR on the BrukerAvance 500 MHz spectrometer with a cryoprobe (Gallagher et al.,
2009) (see Fig. 4). Therefore in our current ongoing lactate labelling
studies using 1,2-13C2 glucose as the substrate, we are making
allowance for background in evaluating the results. For further
considerations about 13C natural abundance background, see
Section 4.3.
A model has been developed by Lee and colleagues using
1,2-13C2 glucose as the substrate, whereby labelling patterns pro-
duced in lactate are used to calculate the fraction of glucose met-
abolic ﬂux that occurs via the pentose cycle (PC), as deﬁned (Lee
et al., 1998). Some of assumptions of the model stated by Lee
and colleagues include that glucose is mostly metabolised by
either the Embden Meyerhof or the pentose pathway, the pentose
phosphate produced is recycled to hexose phosphate, and net loss
of pentose phosphate to nucleic acid synthesis is relatively small.
While a full discussion of the model and all of its assumptions
and limitations is outside the scope of the present article for rea-
sons of length, some of the model’s key features are as follows.
The initial 1,2-13C2 glucose study was in vitro in HepG2 (hepatoma)
cells (Lee et al., 1998). This used GC–MS to measure isotopomer
yields of lactate molecules, i.e. the abundances (expressed as molar
fraction) of ions with no 13C (m0), one 13C (m1) and two 13C (m2),
after correcting for natural abundance of 13C (see Section 4.3); note
that m0 +m1 +m2 = 1. The formula PC = (m1/m2)/[3 + (m1/m2)] was
derived. This model was later applied in vivo in TBI patients, with
intravenous infusion of 1,2-13C2 glucose substrate and ex vivo
GC–MS analysis of lactate labelling in arterial and jugular venous
blood (Dusick et al., 2007); see above. GC–MS reveals how many
13C atoms are present in the molecule, but does not distinguish
the intra-molecular positions of these 13C atoms. Lactate derived
from 1,2-13C2 glucose via glycolysis shows m2 labelling revealed
by GC–MS, due to 13C at both C2 and C3 of lactate adjacent together
within the same molecule, as revealed by NMR (see above). Singly
labelled lactate derived from 1,2-13C2 glucose via the PPP shows m1
labelling revealed by GC–MS. Primarily this single 13C appears at
the C3 position of lactate, although recycling within the PPP may
result in 13C also appearing as single labelling at C2, and as single
labelling at C1, all of which would show as lactate m1 labelling on
GC–MS, without distinguishing between the positions of the 13C
(Lee et al., 1998). Another potential process whereby lactate single
labelling may appear ‘‘scrambled’’ is if 3-13C pyruvate interacts
with the TCA cycle via the action of malic enzyme (ME), producing
lactate with a mixture of single labelling at C3 or C2 (Fig. 3).
The implications of the PPP for energy generation are still not
fully understood. The PPP may be regarded as sacriﬁcing some of
the carbon atoms from the cells’ supply of glucose (which could
otherwise have been used for ATP generation), for the sake of gen-
erating more reducing power (NADPH) and the ability to protect,
repair or build cells. While the PPP appears upregulated by injury,
it also appears up-regulated in cancer (Riganti et al., 2012). Glycol-
ysis also appears upregulated in cancer, a phenomenon termed the
Warburg effect (Warburg 1956). Tumours are often highly glyco-
lytic producing large amounts of lactate regardless of the presence
of oxygen (Bensinger and Christofk 2012; Warburg 1956). Both the
PPP and the Warburg effect may represent potential therapeutic
targets. Unlabelled cerebral microdialysis has been used to study
brain chemistry in glioma patients (Marcus et al., 2010), and in fu-
ture such studies may be extended by use of 13C-labelled
microdialysis.
1.4.2. Anaplerosis
While the well-recognised main entry point into the TCA cycle
is where acetyl-CoA joins with oxaloacetate to form citrate, addi-
tional entry points exist (Owen et al., 2002), termed anaplerotic
reactions (meaning ‘‘ﬁlling up’’ or ‘‘replenishing’’). For example,
while the main pathway for pyruvate involves the enzyme
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CoA that enters the TCA cycle, an anaplerotic pathway involves the
reaction of pyruvate with CO2 by the action of pyruvate carboxyl-
ase (PC) producing oxaloacetate, which is a TCA cycle intermediate
(Fig. 3). Anaplerosis is necessary because as well as the TCA cycle
generating ATP via mitochondrial oxidative phosphorylation, its
intermediates are also sources of amino acids and other molecules
for the cell. A notable exit point is at alpha-ketoglutarate, a TCA cy-
cle intermediate that can be converted to glutamate, and thence to
glutamine (Fig. 3). The TCA cycle thus needs replenishment, pro-
vided by anaplerosis. Fig. 3 illustrates that 13C-labelling patterns
in the emerging glutamate and glutamine can differentiate be-
tween TCA cycle anaplerosis (grey arrows), with pyruvate entry
via PC activity, and mainstream TCA cycle (red arrows), with pyru-
vate entry via PDH and acetyl CoA (Tyson et al., 2003).
2. Microdialysis as a tool for monitoring cerebral metabolism
2.1. Cerebral microdialysis in multimodal monitoring
Monitoring of severe TBI patients in neuro-critical care may in-
clude intracranial pressure, brain tissue oxygen and extracellular
chemistry using microdialysis. Clinical microdialysis catheters
(M Dialysis AB, Stockholm, Sweden) are often inserted through a
burr-hole via a cranial access device e.g. a triple-lumen ‘‘bolt’’
(Technicam, Newton Abbot, UK), which allows up to 2 other probes
(e.g. for intracranial pressure and brain tissue oxygen monitoring)
to be inserted alongside the microdialysis catheter into brain.
Microdialysis catheters can also be inserted via craniotomy, with-
out a cranial access device. While insertion via a cranial access de-
vice orients the catheter perpendicularly into the brain, the
craniotomy situation provides the option of orienting the microdi-
alysis catheter at a shallow angle (i.e. tangentially), to target grey
matter (Gallagher et al., 2009). Grey matter can also be contacted
by a perpendicularly oriented catheter deeper within the brain, be-
cause of the folded nature of the cortex, although this is more dif-
ﬁcult to target. The position of the catheter after insertion can be
veriﬁed using computed tomography (by virtue of the catheter’s
gold tip), or magnetic resonance imaging (MRI) (Fig. 6).
Clinical microdialysis catheters possess a semi-permeable
membrane (nominal molecular weight cutoff either 20 or
100 kDa) that is continuously perfused with ﬂuid, allowing mole-
cules to diffuse across the membrane, to and from the brain’s
extracellular space. For routine clinical monitoring, the catheter
is perfused with a physiological salt solution e.g. CNS perfusionFig. 6. Left panel: Magnetic resonance imaging (MRI) scan, using 3D MP-RAGE sequence
cranial access device) in position, the catheter tip indicated by an arrow (yellow). Sca
Imaging Centre, Dept. of Clinical Neurosciences, University of Cambridge. Right panel: Sch
this ﬁgure legend, the reader is referred to the web version of this article.)ﬂuid (M Dialysis AB, Stockholm, Sweden) and the returning ﬂuid
(microdialysate) is analysed at the bedside utilising automated
enzymatic colorimetric assays (CMA600 or ISCUS microdialysis
analyzer, M Dialysis AB) to measure endogenous glucose, lactate,
pyruvate, glutamate and glycerol. Thus, microdialysis has been
used to monitor glucose delivery and the balance between aerobic
and anaerobic metabolism using the L/P ratio (Timofeev et al.,
2011). For our 13C labelling studies, the 13C labelled substrate
(manufactured by Cambridge Isotope Laboratories Inc., Tewkes-
bury/Andover, MA) is formulated at an appropriate concentration
in CNS perfusion ﬂuid, in a hospital pharmacy manufacturing unit,
with tests for conformity to standard pharmaceutical regulations
for purity, sterility, and freedom from pyrogens. The 13C labelled
substrate formulation is then analysed by high resolution 13C
NMR to ensure that there are no impurities that would compro-
mise the studies. The formulated 13C labelled substrate is then
pumped through the microdialysis catheter in the usual way, and
microdialysates collected for analysis (Gallagher et al., 2009).2.2. Cerebral microdialysis for conveying molecules to and from the
extracellular space
As diffusion across the microdialysis membrane is bi-direc-
tional, microdialysis can deliver molecules (‘‘retrodialysis’’ e.g.
13C-labelled substrates), thereby micro-dosing a region of interest
around the catheter tip, whilst simultaneously collecting the
downstream products in the emerging microdialysate, for analysis
in the laboratory (see Fig. 6 for schematic). In this way, we showed
that infusion of 3-13C-lactate or 2-13C acetate into the brains of TBI
patients via the microdialysis catheter produced 13C signals for glu-
tamine C4, C3 and C2 in the emerging microdialysates, indicating
TCA cycle operation followed by conversion of glutamate to gluta-
mine (Gallagher et al., 2009) (Figs. 3 and 4). Microdialysis can thus
be used to probe the immediate microenvironment around the
catheter by adding chosen 13C-labelled metabolic substrates that
enter the biochemical pathway at different steps, allowing relevant
stages to be investigated. The extent of the region addressed by the
microdialysis catheter is not precisely known. In a combined FDG-
PET and cerebral microdialysis study (without 13C-labelling) in TBI
patients, the cerebral metabolic rate of glucose measurements in a
2 cm region of interest around the microdialysis catheter tip corre-
lated signiﬁcantly with endogenous lactate and pyruvate concen-
trations in the microdialysates (Hutchinson et al., 2009)., at 3 Tesla, showing the brain of a TBI patient with a microdialysis catheter (via a
le bar (green) shows centimetre divisions. Image is courtesy of the Wolfson Brain
ematic of 13C-labelled microdialysis. (For interpretation of the references to colour in
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3.1. Utility of NMR spectroscopy
NMR spectroscopy is well established as a powerful analytical
technique for determining the structures of organic molecules.
Labelling molecules, e.g. with 13C, enables their passage to be
tracked along biochemical pathways, revealing the positions of
the labelled atoms within metabolite molecules contained in bio-
logical samples. An example of 13C-labelled positions within mole-
cules along metabolic pathways is illustrated in Fig. 3. Using
cerebral microdialysis to deliver and collect 13C-labelled molecules
in this context is a novel development (Gallagher et al., 2009).
Examples of 13C NMR spectra of brain microdialysates are illus-
trated in Fig. 4 (Gallagher et al., 2009). These illustrate that micro-
dialysis perfusion with 2-13C acetate or 3-13C lactate produced 13C
signals for glutamine C4, C3 and C2, indicating TCA cycle operation
followed by conversion of glutamate to glutamine in TBI patients’
brains.
In our current ongoing study, microdialysis perfusion with
1,2-13C2 glucose has resulted in 13C signals clearly visible as dou-
blets for the C3 (and C2) of lactate, indicating glycolysis as a major
pathway in TBI patients’ brains as expected. Small enrichment
above natural abundance 13C was measurable in the lactate C3 sin-
glet representing PPP production of lactate in brain. The PPP path-
way is shown schematically in Fig. 5. Examples of the lactate C3
doublet and singlet pattern in 13C spectra of patients’ brain micro-
dialysates are shown in Fig. 7 (Jalloh et al., unpublished data). No
lactate C3 singlet enrichment was detectable in muscle above nat-
ural abundance, though glycolysis-derived lactate (C3 doublet) was
seen.
Our novel combination of 13C-labelled microdialysis with anal-
ysis by high-resolution 13C NMR was the ﬁrst direct demonstration
in humans that the brain can utilise lactate via the TCA cycle
(Gallagher et al., 2009), supporting the ANLS hypothesis (Pellerin
and Magistretti 1994) (see Section 1.3). In our current study the
13C labelling patterns suggest that in TBI patients’ brains lactateFig. 7. Examples of 13C NMR spectra of brain microdialysates from patients who recei
unpublished data). Uninjured brain is normal-appearing brain in a patient operated on fo
patient with diffuse injury. The part of the spectrum illustrated in each case is for the C3 c
the internal standard DSS (2,2-dimethyl-2-silapentane-5-sulfonate sodium salt). The rem
C3 doublet indicated by red stars represents lactate doubly labelled with 13C, produced b
at the neighbouring C2 position within the same molecule. The C3 singlet indicated by
singlet also contains a contribution from endogenous lactate due to the natural abundaproduction is mainly via glycolysis while PPP production of lactate
is minor (see above). Further analyses of samples and data are
ongoing in this study, which is the ﬁrst direct comparison of glycol-
ysis and PPP in human brain by 13C-labelled cerebral microdialysis.
The technique will be extended to other substrates to further elu-
cidate brain chemistry.
3.2. Ex vivo NMR of brain tissue extracts
In conventional studies of cerebral metabolism without micro-
dialysis, 13C-labelled substrates are given intravenously to animals
and then after appropriate time intervals the brains are removed
and extracted (e.g. with perchloric acid) and NMR spectroscopy
of the extracts (liquid solutions) is performed to determine 13C
labelling in the products, either by using direct 13C-observe NMR
e.g. (Bartnik et al., 2007; Bartnik et al., 2005), or indirect 1H-ob-
serve [13C-edited] NMR techniques such as spin-echo difference
e.g. (Tyson et al., 2003). Analysis of brain tissue extracts ex vivo
can give a global whole-brain picture of metabolism, or
alternatively dissection of the brain prior to extraction can give
region-speciﬁc information. Brain tissue extracts encompass both
intra- and extra-cellular molecules, but are not available from
humans unless they are undergoing surgery that excises portions
of brain tissue (e.g. tumours, severe epilepsy), and cannot give a
time-course within-subject; moreover in pre-clinical studies the
animals have to be sacriﬁced.
NMR analysis can be performed directly on ‘‘solid’’ samples e.g.
excised tissues (without having to extract the molecules), by high-
resolution magic angle spinning NMR spectroscopy (HR-MAS
NMR). By means of spinning samples at the ‘‘magic angle’’ (54.7
between the axis of rotation and the magnetic ﬁeld), line-broaden-
ing processes such as dipole–dipole couplings, chemical shift
anisotropy and magnetic susceptibility changes are signiﬁcantly
reduced for solid samples (Andrew et al., 1959). The tissue sample
is placed in a small container termed a rotor (e.g. made of zirco-
nium, 50 ll volume, 4 mm diameter), and is spun (e.g. at
5000 Hz) at a 54.7 angle inside the NMRmagnet. This has been ap-
plied to characterise cells e.g. neuronal and glial cells grown in vitroved 1,2-13C2 glucose (4 mM) perfused via the microdialysis catheter (Jalloh et al.,
r a benign tumour elsewhere in the brain. TBI brain is from a traumatic brain injury
arbon of lactate. Also present in this part of the spectrum is one of the signals due to
ainder of the spectrum, including the main DSS signal (at 0 ppm) is not shown. The
y glycolysis; the C3 signal for 13C is split into 2 peaks by coupling to 13C also present
green stars represents lactate singly labelled with 13C, produced via the PPP; the
nce background of 13C (1.1% of all carbon atoms).
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tissue e.g. a 1H HR-MAS NMR study of human glioblastoma tissue
(Piccirillo et al., 2012), and in 13C-labelling studies, e.g. a 13C HR-
MAS NMR study of brain tissue (21–34 mg samples) from rats gi-
ven intravenous 1,6-13C2 glucose (Risa et al., 2009).
3.3. NMR modalities: direct vs. indirect observation of 13C
NMR spectroscopy for measuring 13C-labelling can be either di-
rect 13C-observe, or indirect 1H-observe [13C-edited]. An example
of the latter is spin-echo difference spectroscopy e.g. (Tyson
et al., 2003). The latter technique generates (a) a 1H NMR spectrum
showing positive signals (upward-pointing peaks) from all protons,
regardless of whether they are attached to 12C or 13C atoms, (b) a
1H spectrum in which protons attached to 12C give positive peaks
but protons attached to 13C give inverted (negative, downward-
pointing) peaks, and (c) a 1H difference spectrum, consisting of
(a) minus (b) so that the peaks from protons attached to 12C are
subtracted out and the peaks for protons attached to 13C appear
positive.
While the indirect 1H-observe [13C-edited] spin-echo difference
modality is more sensitive than the direct 13C-observe, the indirect
modality is more complex to perform and interpret (see Sec-
tion 3.4). An advantage of the spin-echo difference modality is that
it gives information on fractional enrichment, i.e. 13C/(12C + 13C), by
comparing the difference spectrum (c), which reveals protons at-
tached to 13C, with the ‘‘all protons’’ spectrum (a) (see above).
However, the 13C spectrum itself is unseen and there is no informa-
tion on carbons without attached protons (e.g. carboxylate or ke-
tone carbon).
For direct 13C-observe NMR, enrichments are determined by
quantifying the 13C signal (by integration, i.e. measuring the peak
areas, with reference to standards) and quantifying the ‘‘total’’
(labelled plus unlabelled) for the species of interest, either using
direct 1H-observe NMR (integrating the signal with reference to
standards), or by another analytical method such as HPLC or enzy-
matic colorimetric assays. To facilitate integrating NMR signals,
peak ﬁtting is available in NMR software packages (e.g. TopSpin
and Chenomx). Reference standards consist of (a) an internal stan-
dard water-soluble reference substance, e.g. DSS (2,2-dimethyl-2-
silapentane-5-sulfonate sodium salt) which provides a chemical
shift reference point at zero ppm (x-axis of the spectrum) and acts
as a reference for the signal response (y-axis) as it is added at a
known, set concentration into every sample, and (b) an external
standard calibration curve consisting of the molecular species of
interest at an appropriate range of concentrations, plus DSS at
the same ﬁxed concentration as in (a). For direct 13C-observe
NMR, the integrated signal intensity per 13C atom, i.e. the response
factor, is not necessarily uniform (due to a natural effect termed
Nuclear Overhauser Enhancement and other spin relaxation pro-
cesses), so for each carbon position within each molecular species
of interest, calibration has to be carried out.
The NMR modalities of direct 13C-observe, direct 1H-observe,
and indirect 1H-observe [13C-edited] spin-echo difference each
produce ‘‘one-dimensional’’ (1-D) spectra with signal response
(y-axis) plotted vs. chemical shift (x-axis). Another NMR modality
that is recently becoming applied to study metabolism is ‘‘two-
dimensional’’ (2-D) NMR. For 1H-13C 2-D NMR, the analysis uses
a 1H-optimised probe for acquisition with 13C-decoupling, and re-
sults are typically presented as a rectangular plot with a 1H-spec-
trum displayed along one axis (x or y), a 13C-spectrum along the
second axis (y or x), and contours of the cross-peaks representing
1H–13C coupling in the ‘‘body’’ of the rectangle. Joining up the
cross-peaks to the x- and y-axes establishes which carbons are con-
nected to which protons. One type of 1H–13C 2-D spectroscopy is
HSQC (heteronuclear single quantum coherence). This combinesthe high sensitivity of 1H spectroscopy with the high information
content of 1H and 13C and their connectivity. It is more powerful
than 1-D techniques for yielding unambiguous structural / identi-
ﬁcation information, largely overcoming the problems of unre-
solved signals that in some cases affect 1-D spectra (e.g. due to
near-coincidences in chemical shift, and/or overlapping signals).
1H–13C HSQC was one of the techniques used to analyse the prod-
ucts of intravenous U-13C glucose in lung cancer patients, in a sta-
ble-isotope resolved metabolomics study (Fan et al., 2009). We
have begun to use 2-D 1H–13C HSQC in selected cases, for addi-
tional veriﬁcation of labelled products of 13C-labelled microdialy-
sis, after routine 1-D 13C spectra and 1-D 1H spectra. We are also
further interrogating the 1H spectra of the microdialysates by 2-
D 1H–1H DQF-COSY (double quantum ﬁltered correlation
spectroscopy).
3.4. In vivo magnetic resonance spectroscopy
A 13C measurement technique applicable to both animals and
humans is in vivomagnetic resonance spectroscopy (MRS). Though
the description ‘‘nuclear’’ is generally not applied, the fundamental
phenomenon is the same as in NMR. MRS is used in conjunction
with MRI to measure the levels of metabolites in situ in chosen
locations within body tissues, including regions of interest in the
brain and is applied clinically to produce a ‘‘signature’’ which can
assist diagnosis of certain disorders, e.g. tumours.
Microdialysis andMRS are complementary techniques, microdi-
alysis focussing on the extracellular space, with MRS measuring
combined extra- and intra-cellular metabolism. In addition, unlike
microdialysis, which can only report on metabolic processes in the
vicinity of the catheter, localised MRS can interrogate metabolism
in multiple brain regions (using either natural abundance 13C MRS,
or systemically administered 13C-labelled substrate). MRS could
therefore allow comparison of metabolism in different tissue com-
partments (e.g. perilesional vs. normal appearing tissue). Compar-
ison of extracellular chemistry in two sites within the same
patient’s brain necessitates inserting a microdialysis catheter in
each location, which is sometimes performed in clinical research.
MRS can provide scope for non-invasive exploration of regional
chemistry differences in brain.
Routine MRS on clinical MRI scanners usually measures 1H
spectra in unlabelled brains. However, in research studies, direct
in vivo MRS observation of 13C in brain has been performed with
1-13C glucose intravenous infusion in healthy human volunteers
(Gruetter et al., 1994) and in patients (Moreno et al., 2001). These
13C-labelling studies have enabled glucose metabolism to be
tracked to formation of glutamate and glutamine and in some
cases TCA cycle rates have been estimated from the data e.g.
(Mason et al., 1995). Also, 2-13C acetate intravenous infusions in
healthy volunteers have enabled measurement, by direct 13C
in vivo MRS, of astroglial metabolism to glutamate and glutamine
(Lebon et al., 2002). There is much future scope for expanding
the use of in vivo MRS in clinical studies utilising 13C labelling.
An alternative, indirect in vivo MRS method of detecting 13C
labelling in brain utilises 1H-observe [13C-edited] spectroscopy, of-
ten abbreviated as POCE (proton observe, carbon edited) (Chen
et al., 2001). It is more sensitive than directly-observed 13C MRS,
since proton (1H) is inherently a more readily detectable nucleus
than 13C (de Graaf et al., 2011). However design of the pulse se-
quences for acquisition of 1H-observe [13C-edited] spectra, and
the interpretation of the data, is more complex. Also it has less
scope as a screening technique - it works well for certain moieties,
which need to be decided beforehand. The resultant spectra can be
quite complex with incompletely resolved peaks (due to couplings)
and overlapping signals within the narrow ppm scale of the proton
(1H) spectrum, necessitating deconvolution by means of
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serve [13C-edited] approach is that it directly gives 13C fractional
enrichment values, i.e. the total (12C + 13C) and the 13C fraction of
a given metabolite, analogous to the spin-echo difference NMR
done in solution on animal brain tissue extracts ex vivo, e.g. (Tyson
et al., 2003).
Another in vivomodality that has grown over the past decade is
hyperpolarized 13C MRI/MRS (Brindle et al., 2011). While detailed
discussion is outside the scope of the present article, some key
examples can be mentioned. Until very recently, the technique
was limited to pre-clinical studies, for practical reasons. Hyperpo-
larized 1-13C glutamate has been used to study tumour metabo-
lism in cell cultures in vitro and in tumours in vivo in mice
(Gallagher et al., 2011). Hyperpolarized 1-13C pyruvate and 2-13C
pyruvate were used to study mitochondrial metabolism in vivo in
normal rats treated with a putative anticancer agent, dichloroace-
tate that stimulates pyruvate dehydrogenase (Hu et al., 2012). Very
recently, the ﬁrst-in-man in vivo hyperpolarized 13C study was
achieved, in prostate cancer patients, using 1-13C pyruvate (Nelson
et al., 2013). Hyperpolarization, which results in a large but short-
lived increase in signal-to-noise ratio, works best on 13C atoms of
carboxylic acid or carbonyl functional groups (e.g. C1 or C2 of pyru-
vate). Because of the transient effect, the technique is best suited to
study fast steps (e.g. pyruvate conversion to lactate, effected by
lactate dehydrogenase) rather than long sequences of multiple
steps, in metabolic pathways. Hyperpolarization appears probably
too short-lived for the microdialysis timescale. However the 13C-la-
belled species could, in principle, be analysed conventionally after
the hyperpolarization has subsided, so microdialysis could be used
in a complementary role in hyperpolarization studies.4. Strengths and limitations of 13C-labelled microdialysis
4.1. Microdialysis and NMR
Microdialysis is a continuous-ﬂow technique, which is advanta-
geous for monitoring patients, though its inherently low ﬂow rates
place demands on analysis, due to small samples. For our 13C stud-
ies we use 0.3 ll/min, the same as for neurocritical care microdi-
alysis monitoring in non-labelled cases (Timofeev et al., 2011).
We have not adopted higher microdialysis ﬂow rates (e.g. 2 ll/
min), as although these would produce larger volumes the samples
would be more dilute, and high ﬂow rates might theoretically per-
turb the tissue biochemistry. Having a low ﬂow rate (0.3 ll/min)
means better equilibration between the solution in the catheter
and the brain extracellular ﬂuid. To have sufﬁcient material for
13C-NMR necessitates pooling the contents of multiple microdialy-
sate collection vials. At our standard ﬂow rate of 0.3 ll/min, we
have pooled 24 h of microdialysate collection vials per NMR tube
(Gallagher et al., 2009). Our NMR spectrometer is a Bruker Avance
500 MHz (11.7 Tesla magnet), thus 13C spectra are at 125.75 MHz.
With the narrowest conventional NMR sample tubes (3 mm) it is
possible to analyse down to a half-day of microdialysate. Inside
the magnet, the NMR sample tube sits within a device termed a
probe. Ours is a cryoprobe, which possesses greater sensitivity
than non-cryo probe technology. In a cryoprobe, the sample is kept
at ambient (room) temperature while cold helium gas is used cool
the radio-frequency transmitter and receiver coils (ca. 16 K) and
preampliﬁer (77 K), for improved signal-to-noise ratio. Cryoprobe
technology enables acquisition of 13C spectra of pooled microdial-
ysates within a reasonable timeframe. For example, our 24 h-
pooled microdialysates were analysed on NMR for 4096 scans with
a 3s delay between each scan (Gallagher et al., 2009), i.e. an anal-
ysis time of approximately 3.4 h. Without a cryoprobe the 13C spec-
trum would necessitate a day or more of NMR time to acquire,which is impractical. Recently, NMR micro-cryoprobes have be-
come commercially available, for smaller samples (e.g. 30 ll for
Bruker’s micro-cryoprobe), which would enable better time-reso-
lution in measurements of metabolic 13C-labelling in future, mak-
ing it theoretically possible to analyse 2 h pools of microdialysates.
NMR strengths are that it identiﬁes the position of the labelled
atom within the metabolite molecule, very little sample manipula-
tion is required, it is non-destructive, and it can be used for screen-
ing, not requiring prior selection of analytes to seek. 13C-labelled
microdialysis can be used safely for severe TBI patients without
interrupting their standard medical care. 13C is a stable isotope
and not radioactive. 13C-labelled microdialysis micro-doses a small
region of the brain directly, avoiding any issues with import across
the blood–brain barrier. It also avoids any possible adverse effects
associated with systemic dosing, which (in humans) would neces-
sitate intravenous administration of large, expensive amounts of
13C substrate that would be potentially complicated by metabolism
by the liver and/or other non-cerebral tissues. With 13C-labelled
cerebral microdialysis it is only necessary to purchase small
amounts (e.g. 1 or 2 g) of the 13C-labelled substrate to make up
the formulation in CNS perfusion ﬂuid, sufﬁcient for multiple pa-
tients, as amounts and volumes delivered are so small.
Like all microdialysis methodology, 13C-labelled microdialysis is
an invasive technique. Cerebral microdialysis cannot be applied to
healthy volunteers and is limited to patients monitored in neuro-
critical care for severe brain injury (e.g. head injury and certain
types of stroke), and patients undergoing surgery (e.g. severe epi-
lepsy, tumour resection or biopsy). There is thus a problem in ﬁnd-
ing normal brain to act as a control. The best available
approximation is normal-appearing brain in patients undergoing
surgery for benign tumours in a different area of the brain.
Microdialysis is limited to the extracellular pool, so may miss
detecting labelled species if they are predominantly intracellular.
Moreover, microdialysis is a focal technique, limited to monitoring
the immediate vicinity of the catheter (Section 2.2). Information
from 13C-labelled microdialysis may in future be complemented
by studies with in vivo MRS that addresses the whole tissue (com-
bined intracellular and extracellular molecules) in selected re-
gion(s) of interest (Section 3.4).
4.2. Mass spectrometry for measuring 13C-labelling in microdialysates
Mass spectrometry is an alternative to NMR for measuring
13C-labelling in microdialysates. Gas chromatography–mass spec-
trometry (GC–MS) was used to analyse human adipose tissue
microdialysates in healthy volunteers (Gustafsson et al., 2007). In
that study, 1-13C glucose was infused via the microdialysis catheter
and 13C labelling measured by GC–MS in the products lactate and
glycerol recovered in the microdialysates. Apart from that study,
and our study (Gallagher et al., 2009), we are unaware of any other
published studies that used microdialysis to both deliver
13C-labelled substrates and collect the 13C-labelled products.
GC–MS was used to analyse 13C labelling in glutamate, in brain
microdialysates from rats receiving intravenous 2,5-13C2 glucose,
with and without a glutamate uptake inhibitor (Kondrat et al.,
2002). Another study, in rats that received an intravenous infusion
sequence of 2,5-13C2 glucose, 12C glucose, and 15NH4Ac (ammo-
nium acetate) involved in vivo 13C MRS, in vivo microdialysis, 13C
NMR for ex vivo analysis of brain tissue extracts, and GC–MS for
analysis of microdialysates (Kanamori et al., 2002). An advantage
of mass spectrometry is that it can be used for any stable isotope
label, even those not amenable to NMR analysis. For GC-MS, a dis-
advantage is that processing and derivatisation steps are usually
required to prepare the samples for analysis, to render the mole-
cule(s) of interest sufﬁciently volatile. Other ‘‘hyphenated’’ mass
spectrometry techniques not requiring derivatisation, e.g. liquid
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for labelled microdialysis studies.
Mass spectrometry is more sensitive than NMR for the amount
of sample needed, and mass spectrometry gives a direct measure of
percentage enrichment of 13C within the molecule. However, mass
spectrometry usually does not give information about the position
of the 13C label within the molecule, unless suitable fragment ions
are generated. Tandem mass spectrometry (e.g. GC–MS/MS or LC–
MS/MS) offers controlled fragmentation which, depending on the
species in question, may yield positional information on labelling
patterns (Antoniewicz 2013). This methodology has begun to be
applied to metabolic ﬂux analysis, and with future reﬁnement
may gain wider use in this context (Antoniewicz 2013). Position
of the label, determined by NMR is the ‘‘gold standard’’ for verify-
ing the biosynthetic pathway.
4.3. Limitations due to isotope background
An ultimate limitation of 13C labelling is the naturally occurring
background (termed natural abundance) since 1.1% of all carbons
are 13C. This limits the sensitivity of detecting low amounts of
exogenously supplied label, especially when there is a substantial
concentration of the endogenous molecule naturally present. This
limitation is particularly marked when the molecule of interest is
singly labelled with 13C, though can largely be overcome by using
double labelling. Having two 13C atoms adjacent to each other in
the molecule of interest produces a ‘‘signature’’ of doublets in the
13C NMR spectrum. The likelihood of this occurring naturally is
0.012%. However, if a biosynthetic pathway results in loss of one
of the two 13C labelled atoms (as in the PPP, with 1,2-13C2 glucose
substrate), which would then give a singly-labelled product, there
will be a doublet background of 1.1% in the product, due to the one
remaining ‘‘label’’ 13C atom being next to a natural background 13C
atom thereby creating a ‘‘pseudo-doubly labelled’’ situation. Given
that glycolysis is the major pathway converting 1,2-13C2 glucose
into 2,3-13C2 lactate thereby showing lactate C3 (and C2) doublets
that are typically strong signals, the contribution of pseudo-doubly
labelled lactate to the observed C3 doublet signal may be relatively
minor. However, ‘‘reimbursing’’ the C3 singlet PPP-derived lactate
signal by adding on the pseudo-doubly labelled component of
the C3 doublet may increase the estimation of the PPP.
The natural abundance background of 13C also affects mass
spectrometry. The latter is inherently more sensitive than NMR,
so mass spectrometry can be done with smaller amounts of sam-
ple. However, mass spectrometry has the disadvantage (mentioned
earlier) that it does not usually distinguish the intra-molecular
positions of enrichment and in most cases mass spectrometry just
determines the ion intensity ratios of the molecular ions. Thus 13C
enrichments in all positions (carbon atoms) within the molecule of
interest are combined together on mass spectrometry so that the
higher molecular weight of the molecule, the higher the back-
ground signal. So, for example, on mass spectrometry a molecule
with 3 carbons will have a 3.3% (3  1.1%) background contribu-
tion to singly labelled molecular ion (M+1, where M is the molec-
ular weight of the unlabelled molecule) due to natural abundance
13C. Furthermore, derivatisation procedures employed for GC–MS
analysis also contribute to background since the derivatised form
of the molecule contains extra atoms. In contrast, NMR signals
are speciﬁc to each individual carbon position so the background
stays at 1.1%. On mass spectrometry, the background at singly la-
belled molecular ion (M+1) is further increased by the contribu-
tions of the naturally-occurring stable isotopes 2H, 17O and 15N
with natural abundances 0.015%, 0.039% and 0.366% respectively,
each multiplied by the number of H, O and N atoms respectively
per molecule then added onto the 13C background on mass spec-
trometry. These non-13C isotopes do not contribute to thebackground on the 13C NMR spectrum. For doubly-labelled molec-
ular ion (M+2) the natural abundance of 18O (0.201%), multiplied
by the number of O atoms per molecule, contributes a background
on mass spectrometry. Background contributions to M+1 and M+2
from isotopes of silicon will affect silyl-derivatised molecules on
GC–MS, e.g. due to 29Si (4.67%) and 30Si (3.1%). Adoption of sufﬁ-
ciently high-resolution mass spectrometry may be able to discrim-
inate the ‘‘isobars’’ component of background in the molecular ion
due to non-13C isotopes, but the component of background due to
natural abundance 13C would of course remain present.
A further consideration of natural abundance background 13C is
that each step of a biosynthetic pathway may introduce progres-
sive dilution with endogenous molecules, depending on the path-
way and pool size, and any competing, branching, or following-
on pathways that would ‘‘lose’’ molecules. Also, self-dilution
occurs if a molecule labelled at one end breaks into two as part of a
pathway – e.g. in glycolysis, one 1-13C glucose molecule produces
one 3-13C pyruvate and one unlabelled pyruvate. For microdialy-
sates, some labelled species may be missed if they are predomi-
nantly intracellular (e.g. glutamate). Such considerations may help
explain why 13C-labelling was negligible in glutamate or glutamine
in cerebral microdialysates resulting from perfusion of TBI patients’
brainswith1-13Cglucose (2 mM,99%enriched)via themicrodialysis
catheter (Gallagheret al., 2009).Dilutionand losses canbepartlyoff-
set by starting with a high concentration of labelled substrate, at
high% enrichment (e.g. 99%), although increasing the absolute con-
centration (regardless of label) risks perturbing the biochemistry.
13C labelmight theoretically affect some reaction rates, but the rela-
tivemass difference (13C vs. 12C) is so small that any effect is usually
deemed negligible.5. Conclusions and future directions
Using microdialysis to both deliver and collect 13C-labelled mol-
ecules to and from the brain extracellular ﬂuid enables site-speciﬁc
information from patients in a local micro-dosing regimen. For
analysing the microdialysates, NMR spectroscopy is the ‘‘gold stan-
dard’’ powerful tool for tracking 13C labelling, revealing not only
which molecular species are labelled, but also precisely which in-
tra-molecular position(s) the label is in, enabling the biosynthetic
pathway(s) to be deduced. 13C NMR is ideally suited to energy
metabolism studies, where the levels of molecules of interest are
often relatively large, of the millimol/L order, though in principle
NMR is applicable to other biosynthetic pathways. Future adoption
of NMR micro-cryoprobe technology would permit smaller sam-
ples, enabling better time-resolution for the microdialysates by
reducing requirements for pooling. Further downscaling of the
microdialysate sample size requirements is possible with analysis
by mass spectrometry, though at the expense of at least some of
the detailed information on precise intra-molecular position of la-
bel. Even so, mass spectrometry has the potential to track labelling
in smaller time-resolved samples and into low-concentration
intermediates/metabolites that are too low for NMR. Overall,
13C-labelled microdialysis methodology, with analysis by high-
resolution NMR and mass spectrometry, widens the scope of
microdialysis for use in clinical studies of energy metabolism,
drugs and other therapeutic interventions.Acknowledgements
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